Related by context. All words. (Click for frequent words.) 71 riociguat 71 MAGE A3 ASCI 71 ZOLINZA 70 docetaxel Taxotere ® 70 Arranon 69 cytokine refractory 69 sorafenib tablets 69 Allovectin 7 ® 69 Gorlin syndrome 69 SAR# [004] 69 axitinib 69 Aflibercept 69 elotuzumab 69 GSK# [001] 69 Fingolimod 69 CIMZIA ™ 68 Hedgehog Pathway Inhibitor 68 Nexavar sorafenib 68 thalidomide Thalomid 68 Temsirolimus 68 mertansine 68 efalizumab 68 Egrifta 68 teduglutide 68 Velcade bortezomib 68 Hepatocellular Carcinoma HCC 68 DEB# 68 YONDELIS 68 huC# DM4 68 trastuzumab DM1 68 Amrubicin 68 anticancer therapy 67 galiximab 67 relapsed MM 67 lumiliximab 67 canakinumab 67 eltrombopag 67 PROCHYMAL 67 recurrent glioblastoma multiforme 67 receptor tyrosine kinase inhibitor 67 amrubicin 67 midstage clinical 67 sorafenib Nexavar 67 gastrointestinal stromal tumors GIST 67 Pemetrexed 67 panitumumab Vectibix 67 IL# PE#QQR 67 alefacept 67 fosbretabulin 67 pertuzumab 67 palifermin 67 erlotinib Tarceva 67 tipifarnib 67 MGd 67 GW# [003] 67 HuMax EGFr 67 metastatic renal cell carcinoma 67 Golimumab 66 evaluating tivozanib 66 #D#C# 66 GSK# [002] 66 trabectedin 66 budesonide foam 66 Certolizumab pegol 66 GLP toxicology studies 66 Cancidas 66 VA# [002] 66 Tarceva TM 66 vemurafenib 66 PRT# 66 CYT# potent vascular disrupting 66 Adentri 66 Thalomid ® 66 teriflunomide 66 bortezomib Velcade 66 Onconase 66 Canvaxin 66 iniparib 66 Sebivo 66 Ceflatonin 66 PrevOnco 66 Aviptadil 66 oxymorphone ER 66 ACZ# 66 TELINTRA 66 Dasatinib 66 neratinib 66 TNF antagonist 66 Tolvaptan 66 Cariprazine 66 BRIM3 66 INCB# [003] 66 APTIVUS r 66 proteasome inhibitor 66 ganetespib 66 Teriflunomide 66 briakinumab 66 Kamada AAT 66 Evoltra ® 66 phase IIb study 66 Virulizin ® 66 TYZEKA 66 PD LID 66 CCR5 receptor antagonist 66 trastuzumab DM1 T DM1 66 rALLy trial 65 hypereosinophilic syndrome 65 BRAF inhibitor 65 Hycamtin 65 Cloretazine 65 Femara letrozole 65 UPLYSO 65 lenalidomide Revlimid R 65 Aurora kinase inhibitor 65 huN# DM1 65 superficial bladder cancer 65 JAK inhibitor 65 alvespimycin 65 posaconazole 65 Dacogen injection 65 Cimzia TM 65 TACI Ig 65 Sutent sunitinib 65 ruboxistaurin 65 R sorafenib tablets 65 APTIVUS 65 ruxolitinib 65 Telintra 65 Tarceva erlotinib 65 pain palliation 65 TEMODAL 65 Aplidin 65 OvaRex ® MAb 65 Alemtuzumab 65 Iressa gefitinib 65 Plicera 65 Dacogen decitabine 65 TASKi3 65 Asentar 65 BENICAR HCT 65 glatiramer 65 Cethromycin 65 EXJADE 65 mapatumumab 65 visilizumab 65 Phase IIIb study 65 Zolinza 65 LY# [003] 65 beta 1a 65 Atrasentan 65 Xanafide 65 baminercept 65 RAPTIVA 65 Daclizumab 65 Arcalyst 65 Triapine R 65 Aryplase 65 albiglutide 65 rituximab Rituxan 65 multitargeted 65 cediranib 65 mitoxantrone plus 65 PSMA ADC 65 humanised monoclonal antibody 65 tocilizumab 65 ToGA 65 Vitaxin 65 Onrigin 65 INSPIRE Trial Phase III 65 intravenous bisphosphonates 65 Sorafenib 65 IRESSA 65 INC# 65 Noxafil 65 Degarelix 65 sitaxsentan 65 metastatic RCC 65 depsipeptide 65 Xinlay 65 non nucleoside HCV 65 Enzastaurin 65 Fibrillex TM 65 SNT MC# 65 Hedgehog antagonist 65 Dapagliflozin 65 Torisel 65 demonstrated antitumor activity 65 severe hypercholesterolemia 65 gadobutrol 65 preclinically 65 Pazopanib 65 Vidaza azacitidine 65 Octreolin 65 Tesmilifene 65 GnRH agonists 65 Xelox 65 angiogenesis inhibitor 64 alemtuzumab treated 64 imatinib therapy 64 Saforis 64 phase IIb clinical 64 Tamibarotene 64 Rasagiline 64 relapsed ovarian cancer 64 samalizumab 64 adalimumab Humira 64 renal toxicity 64 Eltrombopag 64 AGILECT R 64 bendamustine 64 Aclidinium 64 pediatric acute lymphoblastic 64 CANCIDAS 64 BAY #-# 64 Nexavar ® 64 ixabepilone 64 Proellex TM 64 ocrelizumab 64 vandetanib 64 paliperidone palmitate 64 tolevamer 64 Plenaxis TM 64 pomalidomide 64 papillary renal cell carcinoma 64 Afatinib 64 Aptivus ® 64 IGF 1R inhibitor 64 forodesine 64 biliary tract cancer 64 systemically administered 64 gemcitabine carboplatin 64 rilonacept 64 MyVax 64 Renal Cell Carcinoma RCC 64 Raptiva ® 64 vidofludimus 64 decitabine 64 Mylotarg 64 HCV protease inhibitors 64 Reverset 64 anthracyclines taxanes 64 MNTX 64 enzastaurin 64 pediatric malignancies 64 NVA# 64 Mipomersen 64 Phase Ib clinical 64 midstage trials 64 T#I [002] 64 Darinaparsin 64 SUTENT ® 64 Erbitux cetuximab 64 SPIRIVA HandiHaler 64 dalbavancin 64 mITT population 64 Bezielle 64 eprotirome 64 taxane chemotherapy 64 CALGB # [002] 64 Decitabine 64 Omacetaxine 64 Methylnaltrexone 64 LB# [003] 64 docetaxel Taxotere 64 Hsp# Inhibitor 64 pharmacokinetic PK study 64 Erlotinib 64 SCIg 64 Telbivudine 64 regorafenib 64 favorable pharmacokinetic profile 64 etanercept Enbrel 64 mepolizumab 64 O PPDS 64 RhuDex ® 64 Specifid 64 NV1FGF 64 Pimavanserin 64 basal cell carcinoma BCC 64 dose proportionality 64 relapsing multiple sclerosis 64 ATL# [001] 64 Vernakalant 64 recurrent NSCLC 64 Panzem R NCD 64 REMINYL ® 64 #I TM# 64 deforolimus 64 memantine Namenda 64 gefitinib Iressa 64 CTEPH 64 PROSTVAC TM 64 sunitinib Sutent 64 LEP ETU 64 BARACLUDE ® 64 NATRECOR ® 64 clevidipine 64 KRN# 64 noninfectious uveitis 64 Phase #b/#a 64 TORISEL 64 estramustine 64 MabCampath 64 RSD# oral 64 oral mTOR inhibitor 64 PEG SN# 64 Febuxostat 64 dacetuzumab 64 tipranavir 64 alicaforsen enema 64 HuLuc# 64 BARACLUDE R 64 EVIZON 64 Hepatotoxicity 64 mycophenolate mofetil 64 Kepivance 64 trastuzumab Herceptin ® 64 SNT-MC#/idebenone 64 interferon gamma 1b 64 complete cytogenetic response 64 PSN# [002] 64 Actilon 64 Safinamide 64 oral methylnaltrexone 64 atrasentan 64 recurrent GBM 64 preclinical pharmacokinetic 64 TYGACIL 64 Azedra 64 Valortim R 64 HER2 positive metastatic breast 64 phase IIb trial 64 Navelbine ® 64 IMA# 64 EDEMA3 trial 64 Doxil ® 64 dosage regimens 64 Teriparatide 64 Riluzole 64 LIALDA 64 Traficet EN 64 Fludara ® 64 refractory CLL 64 JAK2 inhibitor 64 Trastuzumab DM1 64 TOLAMBA 64 Zybrestat 64 biologic therapy 64 Iloperidone 64 CAELYX 64 Aldara Cream 64 BEXXAR Therapeutic Regimen 64 rindopepimut 64 PEGylated interferon beta 1a 64 plasma kallikrein inhibitor 64 ziconotide 64 CINTREDEKIN BESUDOTOX 64 erlotinib Tarceva ® 64 Dalbavancin 64 lupus nephritis 64 Muraglitazar 64 nonsmall cell lung cancer 64 ORENCIA R 64 pharmacokinetic interactions 64 AMEVIVE 64 viral kinetics 64 placebo controlled clinical trials 64 cilengitide 64 oral prodrug 64 EGFR TKI 64 Boceprevir 64 Phase IIIb clinical 64 anti angiogenic agents 63 oral FTY# 63 pancreatic neuroendocrine tumors 63 Pertuzumab 63 abiraterone acetate 63 Vorinostat 63 MERLIN TIMI 63 methylnaltrexone 63 ZACTIMA 63 OMNARIS HFA 63 oxaliplatin Eloxatin 63 aleglitazar 63 Gemzar ® 63 dirucotide MBP# 63 Fludara 63 gemifloxacin 63 AVASTIN 63 CCX# 63 Removab 63 Proxinium TM 63 Gliadel Wafer 63 Liprotamase 63 sunitinib malate 63 fingolimod 63 Phase Ib II 63 Targretin capsules 63 fibromyalgia syndrome 63 Gleevec Glivec 63 adecatumumab 63 Tarvacin 63 MIRCERA 63 PREZISTA r 63 refractory metastatic 63 Folotyn 63 Genentech Rituxan 63 SERMs 63 histone deacetylase inhibitor 63 ORENCIA ® 63 TBC# 63 EOquin TM 63 motesanib 63 MGN# 63 olaparib 63 CELVAPAN H#N# 63 Votrient 63 Phenoptin 63 ACTEMRA TM 63 AA Amyloidosis 63 Celebrex celecoxib 63 Ocrelizumab 63 Gleevec imatinib 63 lymphoma CTCL 63 pradefovir 63 RhuDex TM 63 nucleoside analogs 63 Genasense ® 63 non metastatic osteosarcoma 63 sunitinib 63 docetaxel chemotherapy 63 LHRH agonists 63 Squalamine 63 Bosutinib 63 macrolide antibiotic 63 Faslodex 63 nab paclitaxel 63 synthetic retinoid 63 allogeneic HSCT 63 aflibercept 63 Tocosol Paclitaxel 63 metastatic malignant 63 Hydroxyurea 63 Laquinimod 63 cetuximab Erbitux 63 immunomodulatory agents 63 cobiprostone 63 Certican 63 metastatic bladder 63 Tyrosine Kinase Inhibitors 63 KNS # 63 AP# [003] 63 AEG# 63 efficacy endpoint 63 cisplatin gemcitabine 63 Seliciclib 63 nilotinib 63 interferon ribavirin 63 Rezular 63 oral antiviral 63 Alogliptin 63 alkylating agent 63 microtubule inhibitor 63 Tofacitinib 63 dacarbazine chemotherapy 63 APTIVUS ritonavir 63 diabetic neuropathic pain 63 noscapine 63 PROMACTA 63 Targretin 63 apremilast 63 Catena ® 63 Gleevec resistant 63 #mg ATC 63 AVADO 63 PKC# 63 FOLOTYN ® 63 Elvitegravir 63 Vandetanib 63 prospectively defined 63 Amplimexon 63 anti angiogenic therapy 63 EndoTAG TM -1 63 romidepsin 63 Pafuramidine 63 ospemifene 63 docetaxel Taxotere R 63 salmeterol fluticasone 63 PegIFN RBV 63 INCB# [001] 63 Eraxis 63 MEK inhibitor 63 relapsing MS 63 nonclinical studies 63 PEGINTRON TM 63 IBS C 63 micafungin 63 ThermoDox R 63 Kuvan sapropterin dihydrochloride 63 lenalidomide dexamethasone 63 plasma pharmacokinetics 63 casopitant 63 chimeric monoclonal antibody 63 Alinia 63 tigecycline 63 MAXY alpha 63 Tavocept 63 BMS # 63 Irinotecan 63 CIMZIA TM certolizumab pegol 63 Tyrima 63 ZYVOX 63 Syncria 63 zalutumumab 63 alvimopan 63 ACCORD Lipid 63 radiation sensitizer 63 CEQ# 63 BNC# 63 HoFH 63 BR.# 63 placebo controlled clinical 63 OMP #M# 63 Nexavar tablets 63 DAVANAT 63 unresectable tumors 63 Taxol paclitaxel 63 nucleoside analog 63 Kahalalide F 63 Deforolimus 63 acetonide FA 63 Herceptin trastuzumab 63 pegylated interferons 63 pemetrexed Alimta 63 FTY# 63 pegylated liposomal doxorubicin 63 biologic DMARD 63 RG# [001] 63 HDAC Inhibitor 63 AVOREN 63 GRN# 63 Lenocta 63 Romiplostim 63 TKI therapy 63 rufinamide 63 BRIM2 63 TheraCIM 63 Cardiotoxicity 63 Proleukin 63 histone deacetylase HDAC inhibitor 63 GRNVAC1 63 Everolimus 63 SIR Spheres 63 ATL/TV# 63 cinacalcet 63 VEGF inhibitor 63 NovaBay Aganocide compounds 63 reduce serum phosphate 63 Axitinib 63 metastatic colorectal 63 basiliximab 63 ibandronate 63 eosinophilic asthma 63 Androxal TM 63 latanoprost 63 pharmacokinetic equivalence 63 strontium ranelate 63 MabThera rituximab 63 Dendreon Provenge 63 Panzem 63 K ras mutations 63 tarenflurbil 63 Fablyn 63 antineoplastic 63 PegIntron 63 perampanel 63 Taxotere ® 63 pediatric Crohn disease 63 RhuDex 63 OPAXIO 63 HuMax CD4 63 talabostat 63 immunomodulatory therapy 63 null responder 63 YONDELIS R 63 SCH # 63 denileukin diftitox 63 non squamous NSCLC 63 Milnacipran 63 ADAGIO study 63 NAbs 63 SYMMETRY trial 62 Reclast Aclasta 62 anthracycline chemotherapy 62 basal bolus regimen 62 Zevalin consolidation 62 HMG CoA reductase inhibitors 62 HQK 62 malignant ascites 62 Phase Ib study 62 ALK inhibitors 62 UVIDEM 62 Elotuzumab 62 marketed pegylated interferons 62 AQ4N 62 HCV SPRINT 62 selective modulator 62 dosing cohort 62 successfully commercialize Iluvien 62 adult chronic ITP 62 bevacizumab Avastin 62 calcineurin inhibitors 62 cladribine 62 IMGN# 62 Prestara 62 severe hypersensitivity reactions 62 tafamidis 62 Gattex 62 Vimpat lacosamide 62 myelofibrosis polycythemia vera 62 Tanespimycin 62 MyVax R 62 invasive candidiasis 62 Rituxan rituximab 62 LEUKINE 62 mGluR5 NAM 62 INS# [001] 62 ARIKACE ™ 62 mesylate 62 Vertex telaprevir 62 Vidofludimus 62 bicifadine 62 genotypic resistance 62 Alimta pemetrexed 62 chronic idiopathic thrombocytopenic purpura 62 SCCHN 62 randomized Phase IIb 62 raloxifene Evista 62 efaproxiral 62 inhaled AAT 62 DU #b 62 Clevudine 62 glatiramer acetate 62 Ixempra 62 prucalopride 62 Topotecan 62 injectable formulations 62 multiple myeloma MM 62 infliximab Remicade 62 brivaracetam 62 Darusentan 62 Pivotal Phase III 62 SGS# 62 PTK ZK 62 Phase #/#a trial 62 ularitide 62 RELOVAIR ™ 62 Humira adalimumab 62 esophageal candidiasis 62 RhuDex R 62 afamelanotide 62 polymerase inhibitor 62 Crizotinib 62 orBec 62 Silodosin 62 oral ridaforolimus 62 entecavir 62 G#DT 62 rhThrombin 62 OHR/AVR# 62 dose escalation phase 62 busulfan 62 ALA PDT 62 Folfox 62 myelodysplastic myeloproliferative diseases 62 decompensated liver disease 62 generation purine nucleoside 62 ritonavir boosted 62 pharmacodynamic properties 62 BAL# [002] 62 metastatic malignant melanoma 62 Phase #b/#a clinical 62 novel VDA molecule 62 hypersensitivity allergic reactions 62 bazedoxifene 62 MYDICAR 62 peginterferon alpha 2a 62 transthyretin amyloidosis 62 differentiated thyroid 62 Eculizumab 62 Phase IIb clinical trials 62 IgG1 monoclonal antibody 62 epithelial tumors 62 LHRH antagonists 62 guanfacine extended release 62 PF # [002] 62 superficial basal cell carcinoma 62 Tolamba 62 Vimpat R 62 RoACTEMRA 62 bicalutamide 62 Cellcept 62 AMPK activators 62 nitazoxanide 62 clobazam 62 Peginterferon alfa 2b 62 abiraterone 62 ELOXATIN 62 certolizumab 62 Talabostat 62 phase Ib 62 anakinra 62 ximelagatran 62 secondary efficacy endpoint 62 Rezonic 62 multicenter Phase II 62 anti leukemic 62 opioid induced constipation OIC 62 mRCC 62 mTOR inhibition 62 liposomal doxorubicin 62 Ozurdex 62 maximally tolerated dose 62 PEARL SC 62 dexpramipexole 62 Diamyd ® 62 IMiDs ® 62 myopathy rhabdomyolysis 62 AKT inhibitor 62 FUSILEV enhances 62 ULORIC 62 daptomycin 62 surrogate endpoint 62 Marqibo TM 62 HER2 overexpression 62 TNF alpha inhibitor 62 daclizumab 62 EndoTAGTM 1 62 alpha interferons 62 retinal vein occlusion 62 Azixa 62 anti EGFR antibody 62 Allovectin 7 62 darunavir r 62 dasatinib Sprycel 62 indibulin 62 antiarrhythmic drug 62 ponatinib 62 relapsed SCLC 62 endothelin receptor antagonists 62 lintuzumab 62 pancreatic enzyme replacement 62 haematologic 62 Zevalin R Ibritumomab 62 cisplatin chemotherapy 62 CBLC# 62 IOP lowering 62 Zemplar Capsules 62 Carfilzomib 62 calcineurin inhibitor 62 GATTEX ® 62 Archexin 62 Corlux 62 topical calcineurin inhibitors 62 non nucleoside inhibitor 62 TG# [003] 62 Platinol ® cisplatin 62 omega interferon 62 preclinical efficacy 62 torcetrapib atorvastatin 62 Cimzia ® 62 BrachySil TM 62 miconazole Lauriad ® 62 p# biomarker 62 metastatic gastric 62 flavopiridol 62 JAK inhibitors 62 VFEND 62 cytotoxic therapy 62 Anthim 62 phase IIa 62 Rilonacept 62 NP2 Enkephalin 62 Lu AA# 62 DAPT 62 reslizumab 62 LAF# 62 eniluracil 62 volociximab 62 milatuzumab 62 QTc prolongation 62 KRAS status 62 rilpivirine 62 Gleevec imatinib mesylate 62 anti androgen 62 Aliskiren 62 SILENOR 62 TNF inhibitor 62 lenalidomide Revlimid 62 EDEMA3 62 bazedoxifene conjugated estrogens 62 Sym# 62 Forodesine HCl 62 Prosaptide 62 nucleotide analogue 62 standard chemotherapy regimen 62 sargramostim 62 vorinostat 62 octreotide implant 62 glucocorticoid induced osteoporosis 62 relapsed MCL 62 cytostatic 62 Tygacil 62 paclitaxel Taxol R 62 NSABP C 62 florbetaben 62 Resolute DES 62 CTAP# Capsules 62 VaD 62 Zometa zoledronic acid 62 Cladribine 62 metastatic HRPC 62 TLK# 62 dasatinib Sprycel ® 62 Ceplene/IL-2 62 SinuNase TM 62 relapsing remitting MS RRMS 62 inhibitor RG# 62 small molecule Hedgehog 62 Tigecycline 62 Zoraxel 62 antiangiogenic therapy 62 refractory chronic lymphocytic 62 Advexin 62 glufosfamide 62 antiangiogenic agent 62 Onco TCS 62 eritoran 62 Stimuvax R 62 PROSTVAC ® 62 ONGLYZA saxagliptin 62 CIMZIA TM 62 Tasigna nilotinib 62 Increlex R 62 Halaven 62 Subgroup analysis 62 6R BH4 62 follicular lymphoma FL 62 ADP receptor antagonist 62 itraconazole 62 dexanabinol 62 bovine thrombin 62 immune modulating 62 OMAPRO ™ 62 miglustat 62 PREOS 62 EVIZON TM 62 r hGH 62 nanopharmaceutical 62 Taxotere docetaxel 62 Recombinant Human 62 Epratuzumab 62 mTOR inhibitors 62 recombinant interferon 62 Alkeran 62 INVEGA ® 62 Natalizumab 62 tacrolimus ointment 62 Mitoxantrone 62 Neulasta ® 62 brivanib 62 Sanctura XR 62 pegylated interferon alpha 62 DDP# 62 acyclovir Lauriad R 62 CDP# 62 fluvastatin 62 bosutinib 62 terlipressin 62 AIR CF1 62 crizotinib PF # 62 invasive aspergillosis 62 KRAS mutant tumors 62 AERx iDMS 62 Akt inhibitor 62 Arikace 62 rBChE 62 candidates Dyloject TM 62 Sanofi Aventis Taxotere 62 febuxostat 62 investigational humanized monoclonal antibody 62 CCR5 antagonist 62 sipuleucel T 61 Perforomist ™ Inhalation Solution 61 CCR5 mAb 61 gemcitabine cisplatin 61 CONBRIZA 61 velafermin 61 ENMD # 61 Lucrin 61 HRPC 61 Bendamustine 61 tolvaptan 61 LBH# 61 Junovan 61 flutamide 61 constipation OIC 61 inhaled iloprost 61 refractory multiple myeloma 61 Gilead Viread 61 Belimumab 61 Raptiva R 61 castration resistant prostate cancer 61 HuMax CD# 61 NATRECOR R 61 peg interferon 61 Pegloticase 61 R# #mg BID 61 Valdoxan 61 oral rivaroxaban 61 HCV protease 61 UCB Cimzia 61 QLT# 61 dirucotide 61 cannabinor 61 metastatic neuroendocrine tumors 61 Romidepsin 61 Virologic 61 NOXAFIL 61 Onalta 61 Nimotuzumab 61 eribulin mesylate 61 ImmunoVEX HSV2 61 Ambrisentan 61 DXL# 61 refractory gout 61 antitumor effect 61 Zyclara Cream 61 Vertex hepatitis C 61 anti CD3 antibody 61 PF # [001] 61 Subgroup analyzes 61 Avastin bevacizumab 61 Entecavir 61 dual endothelin receptor antagonist 61 ImClone Erbitux 61 Campath alemtuzumab 61 TELCYTA 61 ARCALYST ® 61 pregabalin Lyrica 61 immunomodulatory properties 61 vinorelbine tartrate 61 TYKERB 61 heavily pretreated 61 topically administered 61 figitumumab 61 ASONEP 61 OMNARIS Nasal Spray 61 Meets Primary Endpoint 61 R lenalidomide 61 elacytarabine 61 Emselex 61 raltegravir 61 REMICADE ® 61 Phase IIB 61 PEP# [003] 61 PrevOnco ™ 61 Sapacitabine 61 advanced hepatocellular carcinoma 61 Triapine 61 mCRC patients 61 Non inferiority 61 Amigal 61 GLIADEL R Wafer 61 erythropoietic 61 anticancer activity 61 weekly intravenous infusions 61 XmAb# 61 darapladib 61 Annamycin 61 antibody MAb 61 CHAMPION PCI 61 vascular disrupting agent 61 Olaparib 61 HCV RESPOND 2 61 cabazitaxel 61 Toxicities 61 pivotal bioequivalence 61 romiplostim 61 OncoVex 61 Ozarelix 61 eflornithine 61 relapsed leukemia 61 DMARD 61 Canvaxin TM 61 E2F Decoy 61 Enzyme Replacement Therapy 61 inhaled corticosteroid therapy 61 sorafenib